An independent two-stage DCF analysis by a frontier AI model.
<div class="assumption-grid" data-astro-cid-wbr4wnb2> <div class="assumption-card" data-astro-cid-wbr4wnb2> <div class="label" data-astro-cid-wbr4wnb2>FCF Growth Rate (Phase 1)
<div class="assumption-grid" data-astro-cid-wbr4wnb2> <div class="assumption-card" data-astro-cid-wbr4wnb2> <div class="label" data-astro-cid-wbr4wnb2>FCF Growth Rate (Phase 1)
" data-astro-cid-wbr4wnb2> Long-term nominal GDP growth is around 3%. A conservative 3.5% ceiling ensures the company is not projected to outgrow the broader economy infinitely.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 2.5% | 3.0% | 3.5% | 4.0% | 4.5% |
|---|---|---|---|---|---|
| 2.5% | $24.72 | $20.10 | $16.93 | $14.63 | $12.88 |
| 3.0% | $27.93 | $22.17 | $18.38 | $15.70 | $13.70 |
| 3.5% | $32.10 | $24.72 | $20.10 | $16.93 | $14.63 |
| 4.0% | $37.73 | $27.93 | $22.17 | $18.38 | $15.70 |
| 4.5% | $45.76 | $32.10 | $24.72 | $20.10 | $16.93 |
■ Undervalued vs current price ■ Overvalued vs current price
Boston Scientific is demonstrating exceptionally strong competitive momentum, driven by a robust pipeline of high-margin medical devices and strategic acquisitions. With sales growth accelerating at a remarkable 15.9% year-over-year, it is outpacing many of its large-cap medtech peers. Its portfolio across cardiovascular, neuromodulation, and endoscopy provides a deeply entrenched economic moat characterized by high switching costs for hospitals and surgeons. While pricing power can be pressured by hospital budget constraints, the sheer volume and critical nature of its products make it a highly compelling economic prospect.
Boston Scientific exhibits powerful competitive momentum, highlighted by robust top-line growth and successful commercialization of innovative new products. The company is actively taking market share in key therapeutic areas.
The durability of Boston Scientific's moat is rooted in high switching costs and formidable regulatory barriers to entry. Once a surgeon is trained on its complex devices, the inertia to switch competitors is substantial.
Market sentiment is overwhelmingly positive, driven by accelerating growth, margin expansion, and a very successful M&A strategy that continues to augment its core portfolio.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.